Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst insights, and future rally potential.

Health and Human Services Secretary Robert F. Kennedy Jr. lambasted federal agencies he accused of being overly influenced by ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning and an agile approach, they can be more ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study ...

Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

"I think the common thread is probably that there's a person that's been victimized or discarded or forgotten about by a ...

Driven by attractive margins and significant growth potential, the Indian diagnostics sector has emerged as a preferred bet ...

Some jobs don’t fit any mold. Venom collectors, canal divers, and a few others work in corners of the world most people never ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...